Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ADH -1 (Exherin™), Exherin
ADH-1 · 5 trials · 21 indications
The incidence rates of adverse events will be described by dose level. The frequency of occurrence of overall toxicity, categorized by toxicity grades, will be described.
| Arm | Type | Description |
|---|---|---|
| Treatment (ADH-1, cisplatin, gemcitabine hydrochloride) | EXPERIMENTAL | Patients receive ADH-1 IV over 20-80 minutes on days 1, 4, 8, 11, 15, and 18, cisplatin IV and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 3 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responsive disease may receive maintenance therapy with cisplatin and gemcitabine hydrochloride. |
| Name | Type | Description |
|---|---|---|
| ADH -1 (Exherin™) | DRUG | - |
| ADH-1 | DRUG | 4 gm IV Days 1 and 8 |
| melphalan | DRUG | By Isolated Limb Infusion (ILI), Lower Extremity: 7.5 mg/L (Limb Volume), Day 1 or Upper Extremity: 10 mg/L (Limb Volume), Day 1 |
| ADH -1 and carboplatin | DRUG | - |
| ADH -1 and docetaxel | DRUG | - |
| ADH -1 and capecitabine | DRUG | - |
| Cisplatin | DRUG | Given IV |
| Gemcitabine Hydrochloride | DRUG | Given IV |
| Laboratory Biomarker Analysis | OTHER | Correlative studies |
Inclusion Criteria: * Signed written informed consent * Male and female patients \> or = 18 years of age with a solid tumor(s) refractory to standard curative therapy or for which no curative therapy exists * Histologically proven advanced and/or metastatic solid tumor of one of the following histo...
Top 14 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | Luspatercept, Fedratinib, BMS-986158 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, ABBV-744, IMGN632 |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | PHASE3 | Elritercept |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Incyte Corporation | INCY | 8 | PHASE2 | Ruxolitinib, INCB160058, INCB057643, INCA033989, INCA036978 |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Momelotinib |
| Eli Lilly and Company | LLY | 2 | PHASE1 | LY3410738, LY5830966 |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Damora Therapeutics, Inc. | DMRA | 2 | PHASE2 | GB2064, DMR-001 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE1 | Revumenib |
ADH-1 is an investigational small molecule developed by Fennec Pharmaceuticals Inc. (ticker FENC) for oncology indications. It has been studied in Phase 1 clinical trials in patients with solid tumors and neoplasms, including Ampulla of Vater adenocarcinoma. All four of its recorded trials are completed, and it is not currently listed as an active development program.
ADH-1 has been studied in Phase 1 trials for Ampulla of Vater adenocarcinoma and other neoplasms. One trial, NCT01825603, evaluated ADH-1 with gemcitabine hydrochloride and cisplatin in metastatic pancreatic or biliary tract cancer, a group that includes Ampulla of Vater adenocarcinoma. The drug remains investigational and is not approved for this indication.
ADH-1 is developed by Fennec Pharmaceuticals Inc., which trades under the ticker FENC. The company sponsored the Phase 1 clinical trials of ADH-1 in solid tumors and neoplasms, including studies combining the agent with chemotherapy such as gemcitabine, cisplatin, melphalan, carboplatin, docetaxel, or capecitabine.
ADH-1 is in Phase 1 development. All four of its recorded clinical trials are Phase 1 studies, and all four are completed, with no active trials listed. The drug is investigational and has not been approved by the FDA for any indication.
ADH-1 has been studied in four completed Phase 1 trials: NCT01825603 with gemcitabine and cisplatin in pancreatic or biliary tract cancer, NCT00421811 with normothermic isolated limb infusion of melphalan, NCT00390676 with carboplatin, docetaxel, or capecitabine, and NCT00265057 as an intravenous agent in solid tumors. Total recorded enrollment is 56 patients.
Yes, ADH-1 is also known as Exherin, and it has been referred to as ADH-1 and carboplatin in combination studies. These names refer to the same investigational small molecule developed by Fennec Pharmaceuticals Inc. for oncology indications, so searches for Exherin and ADH-1 lead to the same drug asset.